The pattern of expression of the apoptotic inducer Fas and the apoptotic inhibitor bcl-2 oncogenes immunohistochemicaly in bone-marrow invaded by the non-Hodgkin lymphomasMona M. Rashed1, Noha M. Ragab21General Organization For Teaching Hospitals & Institutes (gothı), Pathology, Cario, Egypt
2Medical Research Institute, Pathology, Alexandria University, Egypt
Apoptosis is a feature commonly seen in tumors; it is an actively regulated cellular process that leads to cell death, in fact the ability to resist apoptosis may seem to offer an advantage to a growing tumor by slowing down the cell loss rate. The present study is a retrospective study aiming at evaluating the Fas/Apo-1, CD95 and bcl-2 oncoproteins immunohistochemically in 30 bone marrow tissue specimens invaded by non- Hodgkin lymphomas (stage IV), 60% of cases were under chemotherapy regimen, while the remainders were still. The study included the significance of the apoptotic inducer Fas/CD95 and apoptotic inhibitor bcl-2 immunoreactivity in relation to a number of clinicopathological variables including age, sex, pattern of malignant cell infiltration in bone marrow, type of malignant cells disseminated and the effect of chemotherapy in relation to apoptotic changes. Fas/CD95 immunoreactivity was positive in 23 cases; 76.7%, positive immunoreactivity was significantly associated with the chemotherapeutic effect (p= 0.0002). On the other side bcl-2 immunoreactivity was positive in 7 cases; 23.3%. A significant association was found between bcl-2 positive immunoreactivity and sex (p= 0.03), pattern of malignant cell infiltration in bone marrow (p= 0.02) and lack of therapy effects (p= 0.0004). As a conclusion (1) Apoptosis is a common feature in non-Hodgkin ’s lymphomas as confirmed by the high incidence of the apoptotic inducer Fas/CD95 positive immunoreactivity; (2) Fas/CD95 and bcl-2 as a tumor markers may work as a useful aid in establishing an apoptosis interpretation in cases of non-Hodgkin ’s lymphomas (stage IV); (3) Fas/CD95 expression translate the chemotherapeutic effects on malignant cells in non-Hodgkin ’s lymphomas; meanwhile the apoptotic inhibitor bcl-2 expression is an independent negative prognostic marker that has been shown to confer resistance to apoptosis. Keywords: Apoptosis, Non-Hodgkin’s lymphoma, Fas/CD95, Bcl-2 proto-oncogenes.
Non-Hodgkin lenfoma tutulumu olan kemik iliklerinde apoptozis indükleyici Fas ve apoptozis inhibitörü olan bcl-2’nin sunum şeklinin immünhistokimyasal olarak gösterilmesiMona M. Rashed1, Noha M. Ragab21General Organization For Teaching Hospitals & Institutes (gothı), Pathology, Cario, Egypt
2Medical Research Institute, Pathology, Alexandria University, Egypt
Apoptozis tümörlerde sık görülen bir olay olup, hücre ölümüne yol açan aktif olarak düzenlenmiş bir hücresel süreçtir. Apoptozise direnç göstermek, hücre kaybını azaltarak tümöre bir avantaj sağlar. Bu çalışmada non-Hodgkin lenfoma evre IV olan ve kemik iliği tutulumu olan 30 hastanın kemik iliği dokusuna retrospektif olarak Fas/Apo-1, CD95 ve bcl-2 onkoprotein açısından immünhistokimyasal inceleme yapıldı. Olguların %60’ı kemoterapi almakta idi. Çalışmada, apoptozisi indükleyen Fas/CD95 inhibe eden bcl-2 immünreaktivitesi ile yaş, cinsiyet, kemik iliğinde malign hücre infiltrasyonu paterni, tipi ve kemoterapi ile olan ilgisi gibi klinikopatolojik değişkenler arasındaki ilişkiye bakıldı. Fas/CD95 23 olguda pozitifti. Pozitif immünreaktivite kemoterapi etkisi ile yakından ilişkili idi (p= 0.0002). Bcl-2 ise 7 olguda pozitifti. Bcl-2 pozitifliği ile cinsiyet arasında (p= 0.03), kemik iliğinde malign hücre infiltrasyon paterni arasında (p= 0.02) ve kemoterapi etkisinin olmaması arasında (p= 0.0004) yakın ilişki saptandı. Sonuç olarak non-Hodgkin lenfomada apoptozis sık görülen bir durumdur. Fas/CD95 ve bcl-2, kemik iliği tutulumu olan non-Hodgkin lenfomada apoptozis yorumu yaptıracak bir tümör işaretleyicisi olarak kullanılabilir. Fas/CD95 ekspresyonu kemik iliğine kemoterapinin etkisini gösterebilirken bcl-2 ekspresyonu apoptozise direnci gösteren bağımsız bir işaretleyici olarak kullanılabilir. Anahtar Kelimeler: Apoptozis, Non-Hodgkin lenfoma, Fas/CD95, Bcl-2.
Mona M. Rashed, Noha M. Ragab. The pattern of expression of the apoptotic inducer Fas and the apoptotic inhibitor bcl-2 oncogenes immunohistochemicaly in bone-marrow invaded by the non-Hodgkin lymphomas. Turk J Hematol. 2004; 21(3): 141-147
Corresponding Author: Mona M. Rashed, Egypt |
|